Sorafenib in Advanced Hepatocellular Carcinoma

Abstract

In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)

Keywords

SorafenibHepatocellular carcinomaMedicineInternal medicineVascular endothelial growth factorCarcinomaVEGF receptorsOncologyCancer research

MeSH Terms

AgedBenzenesulfonatesCarcinomaHepatocellularChemotherapyAdjuvantDisease ProgressionDouble-Blind MethodFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingNiacinamidePhenylurea CompoundsProportional Hazards ModelsProtein Kinase InhibitorsPyridinesSorafenibSurvival Analysisraf Kinases

Affiliated Institutions

Related Publications

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo , Richard S. Finn , Shukui Qin +19 more

In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed...

2018 The Lancet 5118 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Publication Info

Year: 2008
Type: article
Volume: 359
Issue: 4
Pages: 378-390
Citations: 12659
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Sorafenib in Advanced Hepatocellular Carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

12659

OpenAlex

211

Influential

10845

CrossRef

Cite This

APA Style

                            
                                
                                    Josep M. Llovet, 
                                
                                    Sergio Ricci, 
                                
                                    Vincenzo Mazzaferro
                                
                                et al.
                            
                            (2008). 
                            Sorafenib in Advanced Hepatocellular Carcinoma. 
                            New England Journal of Medicine
                            , 359
                            (4)
                            , 378-390.
                            https://doi.org/10.1056/nejmoa0708857
                        

Identifiers

DOI: 10.1056/nejmoa0708857
PMID: 18650514

Data Quality

Data completeness: 86%